Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation

Circulation

Volumn 102, Issue 1, 2000, Pages 104-112

  Li, Danshi ^a   Bénardeau, Agnes ^a   Nattel, Stanley ^a,b,c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Arrhythmia; Dofetilide; Remodeling; Ventricles

Indexed keywords

DOFETILIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0343952982     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.1.104     Document Type: Article

References (29)

1. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
2. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation. 1996;94:2953-2960.
3. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91:1588-1595.
4. Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997;96:4027-4035.
5. Goette A, Honeycutt C, Langberg JL. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94: 2968-2974.
6. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation. 1998;98: 2202-2209.
7. Lee SH, Lin FY, Yu WC, et al. Regional differences in the recovery course of tachycardia-induced changes of atrial electrophysiological properties. Circulation. 1999;99:1255-1264.
8. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100:87-95.
9. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992; 262:809-817.
10. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res. 1998;37:627-635.
11. Cross PE, Arrowsmith JE, Thomas GN, et al. Selective class III antiarrhythmic agents, I: bis(arylalkyl)amines. J Med Chem. 1990;33: 1151-1155.
12. Wiener N, Rosenblueth A. The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex. 1946;16:205-265.
13. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation. 1994;90:2032-2040.
14. Wijffels MC, Dorland R, Allessie MA. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol. J Cardiovasc Electrophysiol. 1999;10:178-193.
15. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther. 1985;232:817-825.
16. Li D, Melnyk P, Feng J, et al. The effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. In press.
17. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512-525.
18. Suttorp MJ, Polak PE, van 't Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol. 1992;69:417-419.
19. Falk RH, Pollak A, Singh SN, et al, for the Intravenous Dofetilide Investigators. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation and flutter. J Am Coll Cardiol. 1997;29:385-390.
20. Norgaard BL, Wachtell K, Christensen PD, et al, and the Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J. 1999;137:1062-1069.
21. Cha Y, Wales A, Wolf P, et al. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy. J Cardiovasc Electrophysiol. 1996;7:809-827.
22. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation. 1986;74:197-204.
23. Boyden PA, Graziano JN. Activation mapping of reentry around and anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol. 1993;4: 266-279.
24. Tai CT, Chen SA, Feng AN, et al. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Circulation. 1998;97:1935-1945.
25. Konings KTS, Kirchhof CJHJ, Smeets JRLM, et al. High density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89:1665-1680.
26. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish investigation of arrhythmia and mortality on dofetilide study group. N Engl J Med. 1999;341:857-865.
27. Sedgwick ML, Lip G, Rae AP, et al. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol. 1995;49:159-166.
28. Pham TD, Fenoglio JJ Jr. Right atrial ultrastructure in chronic rheumatic heart disease. Int J Cardiol. 1982;1:289-304.
29. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observation on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc. 1988;63:552-564.